Related Experiment Video

Updated: Jun 17, 2026

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
10:32

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model

Published on: April 2, 2021

The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of

Joao Borges Fortes Filho1, Gabriela Unchalo Eckert, Fabiana Borba Valiatti

  • 1Departments of Ophthalmology and Pediatrics, Newborn Section, Medical School, Federal University of Rio Grande do Sul and Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. jbfortes@prorop.com.br

Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie
|December 18, 2009
PubMed

Insights

Retinopathy of prematurity (ROP) risk factors vary by gestational age (GA). Extremely preterm infants (GA < 28 weeks) face risks from immaturity, while later preterm infants (GA ≥ 32 weeks) develop ROP due to comorbidities.

Area of Science:

  • Neonatal Ophthalmology
  • Perinatology
  • Public Health

Background:

  • Rising survival rates of preterm neonates have led to increased incidence of retinopathy of prematurity (ROP) globally.
  • Understanding ROP risk factors is crucial for timely intervention and improved outcomes in preterm infants.

Purpose of the Study:

  • To investigate and differentiate the primary risk factors associated with the development of retinopathy of prematurity (ROP).
  • To analyze these risk factors across distinct gestational age (GA) groups in preterm neonates.

Main Methods:

  • Prospective cohort study of 467 preterm infants (birth weight ≤ 1,500 g or GA ≤ 32 weeks).
  • Infants categorized into three GA groups: <28 weeks, 29-31 weeks, and ≥32 weeks.
  • Analysis of perinatal variables including birth weight, GA, oxygen use, blood transfusions, and comorbidities like sepsis.

Main Results:

  • Overall ROP incidence was 23.8%, with severe ROP in 5.1%.
  • Birth weight and blood transfusion volume were significant ROP risk factors across all groups.
  • Extremely preterm infants (GA < 28 weeks) showed higher ROP risk associated with GA, twin status, and erythropoietin use.

Conclusions:

  • ROP in very preterm infants (GA < 32 weeks) is primarily linked to physiological immaturity.
  • In later preterm infants (GA ≥ 32 weeks), ROP development is associated with increased comorbidities, indicating a 'sicker' infant profile.
Abstract

More Related Videos

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...